TRCT
BJDX icon

Tower Research Capital (TRC)’s Bluejay Diagnostics BJDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18K Buy
1,729
+621
+56% +$1.53K ﹤0.01% 4354
2025
Q4 		$2.96K Sell
1,108
-4
-0.4% -$26 ﹤0.01% 4444
2025
Q3 		$6.76K Buy
1,112
+544
+96% +$3.28K ﹤0.01% 4144
2025
Q2 		$3.91K Buy
568
+133
+31% +$1.09K ﹤0.01% 4413
2025
Q1 		$6.49K Buy
435
+296
+213% +$4.54K ﹤0.01% 4038
2024
Q4 		$2.7K Buy
139
+103
+286% +$1.92K ﹤0.01% 4790
2024
Q3 		$907 Buy
36
+14
+64% +$1K ﹤0.01% 5234
2024
Q2 		$3.01K Buy
22
+18
+450% +$15.1K ﹤0.01% 4939
2024
Q1 		$5.76K Buy
4
+2
+100% +$2.76K ﹤0.01% 4494
2023
Q4 		$3.97K Buy
2
+1
+100% +$5.42K ﹤0.01% 5017
2023
Q3 		$6.24K Buy
+1
New +$9.41K ﹤0.01% 4628
2023
Q2 		– Hold
0
– – – 5170
2023
Q1 		– Hold
0
– – – 5047
2022
Q4 		– Hold
0
– – – 4979
2022
Q3 		– Hold
0
– – – 4635
2022
Q2 		– Hold
0
– -$8K – 6074
2022
Q1 		– Hold
0
– – – 4560
2021
Q4 		– Hold
0
– – – 5787

Other funds holding BJDX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $149M AUM
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Tower Research Capital (TRC)'s BJDX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Bluejay Diagnostics (BJDX) stake by 56% in Q1 2026, buying an estimated $1.53K and bringing the position to 1,729 shares worth $3.18K. The position accounts for ﹤0.01% of the portfolio, ranked #4354.

Tower Research Capital (TRC) first reported a position in BJDX in Q3 2023 and has held it in 11 quarters since. The position peaked at $6.76K in Q3 2025. 6 funds tracked by Wall St. Rank hold BJDX as of Q1 2026.

  • Tower Research Capital (TRC) held 1,729 shares of Bluejay Diagnostics worth $3.18K as of Q1 2026.
  • Tower Research Capital (TRC) bought 621 Bluejay Diagnostics shares in Q1 2026, an estimated $1.53K.
  • Bluejay Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4354 holding.
  • Tower Research Capital (TRC) first reported a position in Bluejay Diagnostics in Q3 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Bluejay Diagnostics position peaked at $6.76K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.